Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. This article examines the …Read More >

Kidney diseases are complex conditions caused by a variety of factors, including autoimmune diseases, metabolic disorders, infections, drug side effects, and genetics. Kidney diseases can lead to a range of complications, including kidney failure, anemia, electrolyte imbalances, and nerve damage, thereby affecting the quality of life. To drive breakthroughs in this critical field, WuXi AppTec …Read More >

Women’s health care is crucial not only for the well-being of individual women but also for the health and prosperity of families and communities. Despite significant medical advancements, there remains a concerning gap in the availability of effective drugs for common women-related diseases such as endometriosis, menopause syndromes, polycystic ovary syndrome (PCOS), and various forms …Read More >

Metabolic diseases are considered to arise from multiple factors (such as genetics, diet, age, and environmental factors) and often affect various organs throughout the body.  No single cause is solely responsible for these disorders. To support research in this area, WuXi AppTec offers a comprehensive platform of in vitro and in vivo services.  Our capabilities …Read More >

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >

Casein kinase 2-interacting protein-1 (CKIP-1) performs a critical negative role in the regulation of bone formation. Accumulated evidence strongly supports CKIP-1 as an attractive therapeutic target in osteoporosis.  As a scaffold protein lacking enzymatic activity, CKIP-1 seems to be an undruggable target, and the development of selective small molecule inhibitors targeting CKIP-1 has proven to …Read More >

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >

Introduction: Diabetes is a chronic, metabolic disease resulting from defects in insulin secretion and varying degrees of insulin resistance. Early symptoms include increased thirst and urination, increased hunger, and blurred vision. Progressively, complications such as cardiovascular disease, peripheral neuropathy, nerve damage, myocardial disease, and kidney disease may occur. The prevalence of diabetes at younger ages …Read More >

Salt-inducible kinases (SIKs) have recently emerged as key regulators of oncogenesis, inflammation, and immune responses, making these enzymes an important drug target. The isoform SIK3 is a novel regulator of tumor-intrinsic resistance to cytotoxic T cell attack. To support the discovery of novel SIK3 modulators, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays …Read More >